SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fautrel B, Bourgeois P. Rheumatic disorders: overview. Drugs 2000; 59: 19. In French.
  • 2
    Beaupre GS, Stevens SS, Carter DR. Mechanobiology in the development, maintenance, and degeneration of articular cartilage. J Rehabil Res Dev 2000; 37: 14551.
  • 3
    Enokida M, Teshima R. Morphological features of articular cartilage and synovial membrane in osteoarthritis and rheumatoid arthritis. Clin Calcium 2004; 14: 4550. In Japanese.
  • 4
    Schwamborn K, Caprioli RM. MALDI imaging mass spectrometry—painting molecular pictures. Mol Oncol 2010; 4: 52938.
  • 5
    Ruiz-Romero C, Blanco FJ. Proteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis. Osteoarthritis Cartilage 2010; 18: 5009.
  • 6
    Wilson R, Belluoccio D, Bateman JF. Proteomic analysis of cartilage proteins. Methods 2008; 45: 2231.
  • 7
    Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58: 242031.
  • 8
    Stauber J, MacAleese L, Franck J, Claude E, Snel M, Kaletas BK, et al. On-tissue protein identification and imaging by MALDI-ion mobility mass spectrometry. J Am Soc Mass Spectrom 2010; 21: 33847.
  • 9
    Amstalden van Hove ER, Smith DF, Heeren RM. A concise review of mass spectrometry imaging. J Chromatogr A 2010; 1217: 394654.
  • 10
    Walch A, Rauser S, Deininger SO, Hofler H. MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology. Histochem Cell Biol 2008; 130: 42134.
  • 11
    Gustafsson JO, Oehler MK, Ruszkiewicz A, McColl SR, Hoffmann P. MALDI imaging mass spectrometry (MALDI-IMS)—application of spatial proteomics for ovarian cancer classification and diagnosis. Int J Mol Sci 2011; 12: 77394.
  • 12
    Stauber J, Lemaire R, Franck J, Bonnel D, Croix D, Day R, et al. MALDI imaging of formalin-fixed paraffin-embedded tissues: application to model animals of Parkinson disease for biomarker hunting. J Proteome Res 2008; 7: 96978.
  • 13
    Balluff B, Rauser S, Meding S, Elsner M, Schone C, Feuchtinger A, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 2011; 179: 27209.
  • 14
    Bunch J, Clench MR, Richards DS. Determination of pharmaceutical compounds in skin by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 305160.
  • 15
    Hsieh Y, Chen J, Korfmacher WA. Mapping pharmaceuticals in tissues using MALDI imaging mass spectrometry. J Pharmacol Toxicol Methods 2007; 55: 193200.
  • 16
    Kaletas BK, van der Wiel IM, Stauber J, Guzel C, Kros JM, Luider TM, et al. Sample preparation issues for tissue imaging by imaging MS. Proteomics 2009; 9: 262233.
  • 17
    McDonnell LA, Heeren RM. Imaging mass spectrometry. Mass Spectrom Rev 2007; 26: 60643.
  • 18
    Rauser S, Marquardt C, Balluff B, Deininger SO, Albers C, Belau E, et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010; 9: 185463.
  • 19
    Elsner M, Rauser S, Maier S, Schone C, Balluff B, Meding S, et al. MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. J Proteomics 2012; 72: 4693704.
  • 20
    Meding S, Nitsche U, Balluff B, Elsner M, Rauser S, Schone C, et al. Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J Proteome Res 2012; 11: 19962003.
  • 21
    Hanrieder J, Ljungdahl A, Falth M, Mammo SE, Bergquist J, Andersson M. L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol Cell Proteomics 2011; 10: M111.009308.
  • 22
    El Ayed M, Bonnel D, Longuespee R, Castelier C, Franck J, Vergara D, et al. MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit 2010; 16: BR23345.
  • 23
    Hyc A, Osiecka-Iwan A, Jozwiak J, Moskalewski S. The morphology and selected biological properties of articular cartilage. Ortop Traumatol Rehabil 2001; 3: 15162.
  • 24
    Hedlund H, Mengarelli-Widholm S, Heinegard D, Reinholt FP, Svensson O. Fibromodulin distribution and association with collagen. Matrix Biol 1994; 14: 22732.
  • 25
    Heinegard D, Oldberg A. Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J 1989; 3: 204251.
  • 26
    Sjoberg A, Onnerfjord P, Morgelin M, Heinegard D, Blom AM. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem 2005; 280: 323018.
  • 27
    Pearle AD, Warren RF, Rodeo SA. Basic science of articular cartilage and osteoarthritis. Clin Sports Med 2005; 24: 112.
  • 28
    Fujikawa K, Kawakami A, Tamai M, Uetani M, Takao S, Arima K, et al. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. J Rheumatol 2009; 36: 11269.
  • 29
    Skioldebrand E, Heinegard D, Eloranta ML, Nilsson G, Dudhia J, Sandgren B, et al. Enhanced concentration of COMP (cartilage oligomeric matrix protein) in osteochondral fractures from racing Thoroughbreds. J Orthop Res 2005; 23: 15663.
  • 30
    Clutterbuck AL, Smith JR, Allaway D, Harris P, Liddell S, Mobasheri A. High throughput proteomic analysis of the secretome in an explant model of articular cartilage inflammation. J Proteomics 2011; 74: 70415.
  • 31
    Stevens AL, Wishnok JS, Chai DH, Grodzinsky AJ, Tannenbaum SR. A sodium dodecyl sulfate–polyacrylamide gel electrophoresis– liquid chromatography tandem mass spectrometry analysis of bovine cartilage tissue response to mechanical compression injury and the inflammatory cytokines tumor necrosis factor α and interleukin-1β. Arthritis Rheum 2008; 58: 489500.
  • 32
    Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998; 41: 9971006.
  • 33
    Ekman S, Reinholt FP, Hultenby K, Heinegard D. Ultrastructural immunolocalization of cartilage oligomeric matrix protein (COMP) in porcine growth cartilage. Calcif Tissue Int 1997; 60: 54753.
  • 34
    Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, et al. Cartilage matrix proteins: an acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992; 267: 61326.
  • 35
    Lopez-Franco M, Lopez-Franco O, Murciano-Anton MA, Canamero-Vaquero M, Herrero-Beaumont G, Fernandez-Acenero MJ, et al. An experimental study of COMP (cartilage oligomeric matrix protein) in the rabbit menisci. Arch Orthop Trauma Surg 2011; 131: 116776.
  • 36
    Murphy JM, Heinegard R, McIntosh A, Sterchi D, Barry FP. Distribution of cartilage molecules in the developing mouse joint. Matrix Biol 1999; 18: 48797.
  • 37
    Di Cesare PE, Chen FS, Moergelin M, Carlson CS, Leslie MP, Perris R, et al. Matrix–matrix interaction of cartilage oligomeric matrix protein and fibronectin. Matrix Biol 2002; 21: 46170.
  • 38
    Cole LM, Djidja MC, Bluff J, Claude E, Carolan VA, Paley M, et al. Investigation of protein induction in tumour vascular targeted strategies by MALDI MSI. Methods 2011; 54: 44253.
  • 39
    Homandberg GA. Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments. Front Biosci 1999; 4: D71330.
  • 40
    Rees JA, Ali SY, Brown RA. Ultrastructural localisation of fibronectin in human osteoarthritic articular cartilage. Ann Rheum Dis 1987; 46: 81622.
  • 41
    Hayashi T, Abe E, Jasin HE. Fibronectin synthesis in superficial and deep layers of normal articular cartilage. Arthritis Rheum 1996; 39: 56773.
  • 42
    Thomas CM, Murray R, Sharif M. Chondrocyte apoptosis determined by caspase-3 expression varies with fibronectin distribution in equine articular cartilage. Int J Rheum Dis 2011; 14: 2907.
  • 43
    Du H, Masuko-Hongo K, Nakamura H, Xiang Y, Bao CD, Wang XD, et al. The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processes. Rheumatol Int 2005; 26: 3541.
  • 44
    Mori M, Nakajima M, Mikami Y, Seki S, Takigawa M, Kubo T, et al. Transcriptional regulation of the cartilage intermediate layer protein (CILP) gene. Biochem Biophys Res Commun 2006; 341: 1217.
  • 45
    Lorenzo P, Bayliss MT, Heinegard D. A novel cartilage protein (CILP) present in the mid-zone of human articular cartilage increases with age. J Biol Chem 1998; 273: 234638.
  • 46
    Peters JH, Loredo GA, Benton HP. Is osteoarthritis a ‘fibronectin-integrin imbalance disorder’? Osteoarthritis Cartilage 2002; 10: 8315.
  • 47
    Rock MJ, Holden P, Horton WA, Cohn DH. Cartilage oligomeric matrix protein promotes cell attachment via two independent mechanisms involving CD47 and αVβ3 integrin. Mol Cell Biochem 2010; 338: 21524.
  • 48
    Lorenzo P, Saxne T, Heinegard D, inventors; Anamar Medical AB, assignee. Cartilage intermediate layer protein 2 C1 and its use to differentiate osteoarthritis from rheumatoid arthritis and non-disease conditions. US patent 7812125. 2010 Oct 12.
  • 49
    Loeser RF. Integrins and cell signaling in chondrocytes. Biorheology 2002; 39: 11924.
  • 50
    Iannone F, Lapadula G. The pathophysiology of osteoarthritis. Aging Clin Exp Res 2003; 15: 36472.